NASDAQ:SHPG - Shire Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$175.01 -1.97 (-1.11 %)
(As of 10/21/2018 04:00 PM ET)
Previous Close$175.01
Today's Range$174.83 - $177.73
52-Week Range$123.73 - $182.36
Volume845,253 shs
Average Volume830,732 shs
Market Capitalization$53.20 billion
P/E Ratio11.27
Dividend Yield0.19%
Beta1.19
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1609-6000

Debt

Debt-to-Equity Ratio0.45
Current Ratio1.55
Quick Ratio1.02

Price-To-Earnings

Trailing P/E Ratio11.27
Forward P/E Ratio11.52
P/E Growth1.56

Sales & Book Value

Annual Sales$15.16 billion
Price / Sales3.51
Cash Flow$22.7286 per share
Price / Cash7.70
Book Value$119.43 per share
Price / Book1.47

Profitability

EPS (Most Recent Fiscal Year)$15.15
Net Income$4.27 billion
Net Margins31.06%
Return on Equity13.22%
Return on Assets7.02%

Miscellaneous

Employees23,044
Outstanding Shares303,950,000
Market Cap$53.20 billion

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire declared a dividend on Thursday, August 2nd. Shareholders of record on Friday, September 7th will be given a dividend of $0.168 per share on Friday, October 19th. The ex-dividend date of this dividend is Thursday, September 6th. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire PLC (NASDAQ:SHPG) released its quarterly earnings results on Tuesday, July, 31st. The biopharmaceutical company reported $3.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.67 by $0.21. The biopharmaceutical company had revenue of $3.92 billion for the quarter. Shire had a return on equity of 13.22% and a net margin of 31.06%. Shire's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company earned $3.73 earnings per share. View Shire's Earnings History.

When is Shire's next earnings date?

Shire is scheduled to release their next quarterly earnings announcement on Thursday, November 1st 2018. View Earnings Estimates for Shire.

How can I listen to Shire's earnings call?

Shire will be holding an earnings conference call on Thursday, November 1st at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8558570686.

What guidance has Shire issued on next quarter's earnings?

Shire updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.28. The company issued revenue guidance of $15.4-15.9 billion, compared to the consensus revenue estimate of $15.41 billion.

What price target have analysts set for SHPG?

15 analysts have issued 12-month price objectives for Shire's stock. Their predictions range from $150.00 to $237.00. On average, they anticipate Shire's share price to reach $196.7273 in the next year. This suggests a possible upside of 12.4% from the stock's current price. View Analyst Price Targets for Shire.

What is the consensus analysts' recommendation for Shire?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:
  • 1. According to Zacks Investment Research, "Sales of Shire’s Mydayis showed promise in the first six months of launch. Also, strong performance of Vyvanse, Cinryze and Elaprase continue to drive its top line. The label expansion of Firazyr in pediatrics and approval of Lyophilized Oncaspar in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. Though the adult ADHD space is one of the largest and fastest growing segments of the market, it is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2018)
  • 2. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)
  • 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Prof. Andreas Busch Ph.D., Head of R&D & Chief Scientific Officer (Age 55)

Who are Shire's major shareholders?

Shire's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Aperio Group LLC (0.04%), Reilly Financial Advisors LLC (0.02%), Zweig DiMenna Associates LLC (0.02%), Havens Advisors LLC (0.02%), Dorsey Wright & Associates (0.01%) and Bank of Montreal Can (0.01%).

Which institutional investors are selling Shire stock?

SHPG stock was sold by a variety of institutional investors in the last quarter, including BB&T Corp, Cornerstone Wealth Management LLC, World Asset Management Inc, Huntington National Bank and Raymond James Trust N.A..

Which institutional investors are buying Shire stock?

SHPG stock was purchased by a variety of institutional investors in the last quarter, including Dorsey Wright & Associates, Havens Advisors LLC, Zweig DiMenna Associates LLC, Aperio Group LLC, Seven Eight Capital LP, Bank of Montreal Can, Bremer Trust National Association and Atria Investments LLC.

How do I buy shares of Shire?

Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $175.01.

How big of a company is Shire?

Shire has a market capitalization of $53.20 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.

What is Shire's official website?

The official website for Shire is http://www.shire.com.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]


MarketBeat Community Rating for Shire (NASDAQ SHPG)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  1,008 (Vote Outperform)
Underperform Votes:  541 (Vote Underperform)
Total Votes:  1,549
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel